GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control
Type 2 diabetes and chronic kidney disease form a high-risk cardiorenal phenotype in which treatment goals extend beyond reduction of glycated hemoglobin. This structured narrative, critical, and descriptive review examined PubMed/MEDLINE, the Cochrane Library, and current American Diabetes Association and Kidney Disea...